[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-varices-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-varices-bleeding":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,75,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100054285","cyanoacrylate-glue-versus-absorbable-gelatin-sponge-for-gastric-varices-100054285",false,"NCT07699354","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Gastric Varices","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Endoscopic Treatment of Gastric Varices (CoAGS-GV): A Randomized, Patient- and Assessor-Blinded, Non-Inferiority Trial","CoAGS-GV","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Gastric varices deemed suitable for EUS-guided endoscopic treatment.\n* History of suspected gastric variceal bleeding or active gastric variceal bleeding, with treatment intended for secondary prophylaxis.\n* Ability to provide informed consent directly or through a substitute decision maker.\n* Willingness and ability to undergo clinical follow-up, EUS assessment, and CT imaging.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent directly or through a substitute decision maker.\n* No gastric varix present, or gastric varix too small or not amenable to combination therapy.\n* Contraindication to therapeutic EUS or endoscopy.\n* Contraindication to any study material used in the assigned treatment arm.\n* Contraindication to contrast-enhanced CT, if not clinically manageable.\n* Inability to complete planned follow-up.\n* Pregnancy.\n* Any clinical situation in which the treating endoscopist determines that randomization would be unsafe or inappropriate.","ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study compares two endoscopic ultrasound-guided treatments for gastric varices, which are enlarged veins in the stomach that can bleed. Both treatments use small coils placed into the varix. One group will receive coils with cyanoacrylate medical glue, and the other group will receive coils with absorbable gelatin sponge.\n\nThe purpose of the study is to determine whether absorbable gelatin sponge with coils is not worse than cyanoacrylate glue with coils for closing off gastric varices, and to compare safety outcomes. Participants will be randomly assigned to one of the two treatment groups. Participants and outcome assessors will not know which treatment was used, but the doctor performing the procedure will know.\n\nAfter the procedure, participants will be followed for up to 12 months. Follow-up may include clinical assessments, questionnaires about health and quality of life, CT imaging shortly after the procedure, and repeat endoscopic ultrasound assessments to evaluate whether the gastric varix has been successfully treated.",[27,28,29],"Gastric Varices Bleeding","Gastric Varices","Portal Hypertension",[31,32,33,34,35,36,37,38,39],"Endoscopic ultrasound","EUS-guided therapy","Portal hypertension","Cyanoacrylate glue","Absorbable gelatin sponge","Gelfoam","Coil embolization","Variceal obliteration","Secondary prophylaxis","NOT_YET_RECRUITING","2026-07-09",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":21},"2026-08-01",{"date":48,"type":21},"2029-08-01",{"name":50,"class":51},"Unity Health Toronto","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":52},"100596720","efficacy-and-safety-of-contrast-eus-guided-tissue-gluecoil-devascularization-vs-brto-for-preventing-recurrent-gastric-variceal-bleeding-100596720","NCT07049146","Efficacy and Safety of Contrast EUS-Guided Tissue Glue\u002FCoil Devascularization vs. BRTO for Preventing Recurrent Gastric Variceal Bleeding","Efficacy and Safety of Contrast Endoscopic Ultrasound-Guided Tissue Glue\u002FCoil Devascularization vs. Balloon-Occluded Retrograde Transvenous Obliteration for Preventing Recurrent Gastric Variceal Bleeding: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 75 years old;\n\n  * Liver cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);\n\n    * Experienced bleeding of gastroesophageal varices (GVs) (GOV1, GOV2, or IGV1) within 5 days to 1 year (bleeding lesions observed under endoscopy originating from GVs, or no other bleeding lesions except GVs were found);\n\n      * Presence of spontaneous portosystemic shunts that are technically feasible for BRTO; ⑤ Willing to participate in this clinical study, comply with the study requirements, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Previously received vascular interventional therapy for preventing rebleeding of GVs;\n\n  * Eligible for variceal ligation treatment of GOV1;\n\n    * Non-cirrhotic portal hypertension (including regional portal hypertension);\n\n      * Previously underwent surgical and interventional shunt procedures;\n\n        * Presence of contraindications to endoscopic or interventional treatment; ⑥ Extensive portal vein thrombosis, cavernous transformation of the portal vein;\n\n          ⑦ Massive ascites;\n\n          ⑧ Concurrent advanced liver cancer or other malignant tumors with a predicted lifespan of less than 3 months;\n\n          ⑨ Concurrent severe diseases of other organs such as the heart, lungs, and kidneys;\n\n          ⑩ Pregnant or lactating women.","75 Years",{"count":62,"type":21},242,[24],"The goal of this clinical trial is to compare the effectiveness of EUS-guided tissue glue\u002Fcoil injection and BRTO in preventing rebleeding of gastric varices (GVs) in patients with portal hypertension and GVs (including those with esophageal varices, ascites, or hepatic encephalopathy). The main questions it aims to answer are:\n\nIs the 1-year all-cause rebleeding rate of EUS-guided tissue glue\u002Fcoil injection for GVs non-inferior to that of the BRTO group? Does EUS-guided tissue glue\u002Fcoil injection differ from BRTO in the incidence of decompensated portal hypertension events (variceal bleeding, overt hepatic encephalopathy, ascites) and survival rate post-treatment?\n\nResearchers will compare patients randomized 1:1 to the EUS-guided tissue glue\u002Fcoil injection arm vs. the BRTO arm to see if there are differences in rebleeding rates and complications.\n\nParticipants will:\n\nReceive EUS-guided tissue glue\u002Fcoil injection or BRTO. Take carvedilol long-term (if no contraindications) to reduce portal pressure. Undergo follow-up assessments at 1, 3, 6, and 12 months ±7 days.",[27],"2025-07-02",{"date":68,"type":44},"2025-07-03",{"date":70,"type":21},"2025-07-30",{"date":72,"type":21},"2028-06",{"name":74,"class":51},"West China Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":52},"100567589","detachable-clip-assisted-endoscopic-cyanoacrylate-injection-in-the-treatment-of-gastric-varices-100567589","NCT06670157","Detachable Clip-assisted Endoscopic Cyanoacrylate Injection in the Treatment of Gastric Varices","Detachable Clip-assisted Endoscopic Cyanoacrylate Injection in the Treatment of Gastric Varices Under X-ray Perspective","Inclusion Criteria:\n\n* The subject voluntarily signs the informed consent for this experiment; According to clinical manifestation, laboratory examination, imaging examination, or liver biopsy in the diagnosis of liver cirrhosis patients; The endoscopy diagnosed gastric varices (gastroesophageal varices, gastroesophageal varices type 2 or type 1 isolated gastric varices type 1); High risk of gastric varices or has a history of gastric varices bleeding. The initial fluid resuscitation patients before or after the recovery hemodynamic stability; The age of 18 years old or more.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old; Regional portal hypertension; Always have a liver transplant, via the jugular intrahepatic portal vein system bypass or splenectomy combined varices cut-out art history; A concurrent hepatorenal syndrome and\u002For multiple organ failure; Significant impact on survival of malignant tumor; Pregnancy or lactation; A known allergy to iodine.","80 Years",{"count":84,"type":21},6,[24],"A single-arm exploratory clinical study design was used to evaluate the safety and efficacy of a \"modified sandwich injection\" of tissue glue assisted by a detachable clip for the treatment of gastric varicose veins.",[27],"RECRUITING","2024-10-31",{"date":91,"type":44},"2024-11-01",{"date":93,"type":44},"2024-05-01",{"date":95,"type":21},"2025-10-30",{"name":97,"class":51},"Yu Chang",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100525519","preemptive-tips-for-gastric-variceal-bleeding-in-patients-with-cirrhosis-100525519","NCT06122792","Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis","Preemptive Transjugular Intrahepatic Portosystemic Shunt for Gastric Variceal Bleeding in Patients With Cirrhosis: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);\n* Admission due to acute bleeding from gastric varices (IGV1 or GOV2).\n\nExclusion Criteria:\n\n* Prior treatment with TIPS or surgical shunt;\n* Presence of contraindications to endoscopic treatment, carvedilol, or TIPS;\n* Presence of hepatocellular carcinoma exceeding Milan criteria;\n* Presence of other systemic malignant tumors with expected survival time not exceeding 6 months;\n* Presence of uncontrollable infection or sepsis;\n* Presence of cardiac, pulmonary, or renal failure;\n* Pregnant or lactating women;\n* Refusal to sign the informed consent form.",{"count":106,"type":21},144,[24],"The prevalence of gastric varices is approximately 20%. It is important to note that gastric varices tend to bleed more severely, have a higher morbidity and mortality rate, and have a 35% to 90% risk of rebleeding after the cessation of acute hemorrhage. Because of the relatively low prevalence of gastric varices, the existing clinical studies have many deficiencies, and there is much controversy in the academic community, the optimal treatment and prevention strategies for gastric varices have not yet been fully defined.\n\nIn the last few years, important advances have been made in the treatment and prevention of gastric variceal bleeding in patients with cirrhosis. Experts agree that the combination of pharmacological and endoscopic injection of tissue adhesives should be the first line of therapy in the acute bleeding episode from isolated gastric varices (IGV1) or type 2 gastroesophageal varices (GOV2) varices; whereas transjugular intrahepatic portosystemic shunt (TIPS) is considered a rescue therapy. TIPS has been shown to effectively prevent variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy and\u002For liver failure. In this sense, a recent randomized controlled trial (RCT) in fundal variceal bleeding showed that an early TIPS, performed during the first 5 days after patient admission resulted in a significant decrease in failure to control bleeding and early and late rebleeding. However, the study was conducted for 4 years and only included 25 patients. Due to insufficient sample size, it was unable to reflect whether priority TIPS can bring survival benefits to patients with gastric variceal bleeding. Therefore, there is an urgent need for multi-center clinical studies with large samples to provide high-quality evidence in the field of prioritizing TIPS for the treatment of acute gastric variceal bleeding.\n\nThe present study aims to compare the preemptive TIPS (performed during the first 72 hours after endoscopy) with standard second prophylaxis (endoscopic injection of tissue adhesives plus carvedilol) for patients with acute bleeding from gastric varices (IGV1 or GOV2). The primary outcome will be a 6-week mortality from inclusion.",[29,27,110],"Portosystemic Shunt","2023-11-03",{"date":113,"type":44},"2023-11-08",{"date":115,"type":21},"2024-01",{"date":117,"type":21},"2026-12",{"name":74,"class":51}]